Physician profile
Benjamin B Storey
NPI 1548386394
$5,359.05
in general payments reported to CMS, 2019-2025
22 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,415 · 2020: $181 · 2021: $18.84 · 2022: $208 · 2023: $447 · 2024: $1,969 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,890 · Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,889.92 |
| Food and Beverage | $646.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,074.50 | 2019 | |
| Procept Biorobotics Corporation | $1,889.92 | 2024 | Aquabeam System |
| Astellas Pharma US INC | $289.78 | 2019-2022 | |
| Medtronic, INC. | $241.42 | 2022-2024 | Interstim, Mcgrath Mac |
| Boston Scientific Corporation | $142.54 | 2019-2025 | Lithovue, Tria Firm |
| Sumitomo Pharma America, INC. | $123.34 | 2023-2025 | Gemtesa |
| Coloplast Corp | $83.86 | 2020-2025 | Speedicath |
| Medtronic USA, INC. | $66.44 | 2019-2020 | |
| Urovant Sciences INC | $59.55 | 2022 | |
| Axonics, INC. | $54.32 | 2020-2024 | Bulkamid, Axonics |
| Urogen Pharma, INC. | $47.43 | 2025 | |
| Ambu INC. | $46.52 | 2020-2025 | |
| Antares Pharma, INC. | $37.96 | 2019-2023 | Tlando, Nocdurna, Xyosted |
| Neotract INC. | $34.61 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $27.29 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $26.64 | 2023 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Halozyme INC | $23.27 | 2023 | |
| Endo Pharmaceuticals INC. | $22.38 | 2019 | |
| 180 Medical, INC. | $18.58 | 2024 | Gentlecath |
| Ferring Pharmaceuticals INC. | $16.65 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.29 | 2019 | |
| Tolmar, INC. | $15.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Storey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.